Medica is pleased to announce that JCA Seminars has rebranded to Educate by Medica. This marks an exciting new chapter as Medica continues to evolve and strengthen its commitment to supporting professional development within the healthcare community.
Deciphex, a leader in AI-powered digital pathology, has closed its Series C financing, raising $32.3 million to address the acute global pathology crisis. Led by Molten Ventures with significant participation from ACT Venture Capital, Seroba, Charles River Laboratories (NYSE: CRL), IRRUS Investments, HBAN Medtech Syndicate and Nextsteps Capital, the funding will advance Deciphex's mission to democratize access to high-quality pathology through a technology-enabled global network of pathologists.
Although AI models have demonstrated immense potential for analyzing complex data, their ‘black box’ nature often raises concerns, particularly when AI tools are used for cancer diagnosis and clinical decision making. However, a recent study conducted by researchers at Urmia University and Carleton University may have found a solution that bridges the gap between the analytical capabilities and the limited interpretability of AI tools.
A 10-year-old intact male Staffordshire Bull Terrier was presented to the veterinary clinic with a history of an enlarged popliteal lymph node on the right hind limb. A fine-needle aspiration (FNA) was performed, and the sample was submitted to NationWide Laboratories in the UK for evaluation.
In this episode of PathPulse: Pathology Innovators in Action, we were thrilled to welcome neuropathologist Margaret Flanagan, MD, talk with us about what is missing from digital pathology, highlighting spatial transcriptomics, multi-omics, and more.
Indica Labs announced today that Molecular Pathology Laboratory Network, Inc. (MPLN), a leader in laboratory medicine, hematopathology, and solid tumor oncology testing, has selected the HALO AP® platform from Indica Labs to deliver digital pathology services to both clinical reference labs and biopharma clients. HALO AP® is now in the final stages of clinical validation in MPLN’s CAP/CLIA-certified laboratory, where it is being prepared for initial deployment as a laboratory developed test (LDT) in the setting of urothelial bladder cancer and myeloid neoplasms. Additional disease indications will be validated in HALO AP® as LDTs in a stepwise manner once the initial indications are fully deployed.
Source LDPath, a division of Source BioScience, has been accredited by UKAS to ISO 15189:2022 standards at its Chichester site (UKAS no. 9571). This complements the earlier accreditation secured by its Nottingham laboratory, demonstrating the organisation's commitment to high standards in clinical laboratory quality and competence.
2023 Company of the Year Winner Deciphex are invited onstage. CEO Donal O’Shea reflects on the past year and the benefits of entering the Irish Medtech Awards.
In this insightful interview, Source LDPath‘s Sanj Lallie, Digital Integrations Director, sits down with Lucy Astill, Market Access Manager, to delve into the world of Digital Pathology.
The digital pathology (DP) landscape has grown globally with a revenue of just under $800 million in 2021, with the initial growth attributed to the COVID-19 pandemic, which enabled the pathologist to render remote diagnosis and allowed for continued services to the patients to more than $1 billion in 2024, and projected to increase to about $2 billion by 2027 (Figure 1) in clinical and research settings with the continuous rising trend expected to transition to the next decade. Additionally, a 15% growth in DP adoption by the healthcare community versus a minuscule initial market footprint in the last 5 years corroborates the interest shown by pathologists in using this technology.
